Platelet Transfusion Refractoriness

Launched by INSTITUT DE CANCÉROLOGIE STRASBOURG EUROPE · May 30, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Platelet Transfusion Refractoriness, which can happen after patients receive many platelet transfusions. This condition makes it difficult for patients with low platelet counts to benefit from these transfusions. The trial aims to better understand why this occurs and how to improve treatment for those affected.

To participate in the study, you need to be an adult patient who has either received a stem cell transplant or is undergoing treatment for acute leukemia and requires platelet transfusions. The trial is currently looking for participants and is open to all genders. If you join, you can expect to help researchers learn more about this complication, which could lead to better care for patients in the future. It is important to note that patients under guardianship or those who are minors are not eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient with Hematopoietic stem cells graft (autograft or allograft) or with acute leukemia with the indication of platelet transfusion.
• Exclusion Criteria:
• • Patient under guardianship
• • Minor patient